Detection of undiagnosed diabetes and other hyperglycemia states - The atherosclerosis risk in communities study

被引:33
作者
Schmidt, MI
Duncan, BB
Vigo, A
Pankow, J
Ballantyne, CM
Couper, D
Brancati, F
Folsom, AR
机构
[1] Univ Fed Rio Grande do Sul, Sch Med, Grad Studies Program Epidemiol, BR-90035003 Porto Alegre, RS, Brazil
[2] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA
[3] Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA
[4] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[5] Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC USA
[6] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
关键词
D O I
10.2337/diacare.26.5.1338
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
OBJECTIVE - To evaluate screening strategies based on fasting plasma glucose (FPG), clinical information, and the oral glucose,tolerance test (OGTT) for detection of diabetes or other hyperglycemic states impaired fasting glucose (IFG) and impaired glucose tolerance-meriting clinical intervention. RESEARCH DESIGN AND METHODS - We studied 8,286 African-American and white men and women without known diabetes, aged 53-75 years, who received an OGTT during the fourth exam of the Atherosclerosis Risk in Communities Study. Using a split sample technique, we estimated the diagnostic properties of various clinical detection rules derived from logistic regression modeling. Screening strategies utilizing FPG, these detection rules, and/or the OGTT were then compared in terms of both the fraction of hyperglycemia cases detected and the sample fraction receiving different screening tests and identified as screen positive. RESULTS - Screening based on the IFG cut point (greater than or equal to 6.1 mmol/l), followed by a clinical detection rule for those below this Value, detected 86.3% of diabetic case subjects and 66.0% of all hyperglycemia cases, identifying 42% of the sample as screen positive. Applying an OGTT for those positive by the rule. provides diagnostic labeling and reduces the fraction that is screen positive to 29%. Another strategy, to apply an OGTT to those with an FPG cut point between 5 . 6 and 6.1 mmol/l, also identifies 29% of the sample as screen positive, although it detects slightly fewer hyperglycemia cases. CONCLUSIONS - Screening strategies based on FPG, complemented, by clinical detection rules and/or an, OGTT, are effective and practical in the detection of hyperglycemic states meriting clinical intervention.
引用
收藏
页码:1338 / 1343
页数:6
相关论文
共 25 条
[1]
Performance at a predictive model to identity undiagnosed diabetes in a health care setting [J].
Baan, CA ;
Ruige, JB ;
Stolk, RP ;
Witteman, JCM ;
Dekker, JM ;
Heine, RJ ;
Feskens, EJM .
DIABETES CARE, 1999, 22 (02) :213-219
[2]
Barriga KJ, 1996, DIABETES RES CLIN PR, V34, pS17, DOI 10.1016/S0168-8227(96)90004-2
[3]
Borch-Johnsen K, 1999, LANCET, V354, P617
[4]
Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women [J].
Buchanan, TA ;
Xiang, AH ;
Peters, RK ;
Kjos, SL ;
Marroquin, A ;
Goico, J ;
Ochoa, C ;
Tan, S ;
Berkowitz, K ;
Hodis, HN ;
Azen, SP .
DIABETES, 2002, 51 (09) :2796-2803
[5]
ADVANCES IN STATISTICAL METHODOLOGY FOR THE EVALUATION OF DIAGNOSTIC AND LABORATORY TESTS [J].
CAMPBELL, G .
STATISTICS IN MEDICINE, 1994, 13 (5-7) :499-508
[6]
Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077
[7]
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]
Counterpoint: The oral glucose tolerance test is superfluous [J].
Davidson, MB .
DIABETES CARE, 2002, 25 (10) :1883-1885
[9]
Griffin SJ, 2000, DIABETES-METAB RES, V16, P164, DOI 10.1002/1520-7560(200005/06)16:3<164::AID-DMRR103>3.0.CO
[10]
2-R